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AbstrACt
Introduction Graves’ disease (Graves’ hyperthyroidism) 
is a challenging condition for the young person and 
their family. The excess thyroid hormone generated 
by autoimmune stimulation of the thyroid stimulating 
hormone receptor on the thyroid gland can have a 
profound impact on well-being. Managing the young 
person with Graves’ hyperthyroidism is more difficult than 
in older people because the side effects of conventional 
treatment are more significant in this age group and 
because the disease tends not to resolve spontaneously in 
the short to medium term. New immunomodulatory agents 
are available and the anti-B cell monoclonal antibody 
rituximab is of particular interest because it targets cells 
that manufacture the antibodies that stimulate the thyroid 
gland in Graves’.
Methods and analysis The trial aims to establish 
whether the combination of a single dose of rituximab 
(500 mg) and a 12-month course of antithyroid drug 
(usually carbimazole) can result in a meaningful increase 
in the proportion of patients in remission at 2 years, the 
primary endpoint. A single-stage, phase II A’Hern design is 
used. 27 patients aged 12–20 years with newly presenting 
Graves’ hyperthyroidism will be recruited. Markers of 
immune function, including lymphocyte numbers and 
antibody levels (total and specific), will be collected 
regularly throughout the trial.
Discussion The trial will determine whether the 
immunomodulatory medication, rituximab, will facilitate 
remission above and beyond that observed with antithyroid 
drug alone. A meaningful increase in the expected 
proportion of young patients entering remission when 
managed according to the trial protocol will justify 
consideration of a phase III trial. Ethics and dissemination 
The trial has received a favourable ethical opinion (North 
East - Tyne and Wear South Research Ethics Committee, 
reference 16/NE/0253, EudraCT number 2016-000209-
35). The results of this trial will be distributed at 
international endocrine meetings, in the peer-reviewed 
literature and via patient support groups.
trial registration number ISRCTN20381716.
IntroDuCtIon 
Graves’ hyperthyroidism, an autoimmune 
disorder, has an annual incidence of 1 in 
10 000 adolescents (~700 per year) in the 
UK.1 The standard first-line treatment is the 
antithyroid drug (ATD) carbimazole (CBZ), 
which prevents the thyroid gland from manu-
facturing thyroid hormone and has an immu-
nomodulatory effect.2 While CBZ will render 
most patients biochemically euthyroid in 
appropriate doses, only 50% of adults will 
remit following a standard 2-year course of 
ATD. The proportion of children and adoles-
cents entering remission is considerably 
strengths and limitations of this study
 ► This is a group of patients in whom current therapy 
does not usually result in disease resolution, with 
only 20%–30% remitting after a 2-year course of 
antithyroid drug treatment with carbimazole; hence 
there is a significant unmet need.
 ► The behaviour of the disease in the young patient 
with Graves’ hyperthyroidism in terms of likelihood 
of remission following antithyroid (thionamide) drug 
is consistent between reported studies    This will 
help us to comment on the potential impact of the 
trial intervention in this exploratory trial without 
studying a large number of patients.
 ► We will be looking at a range of markers of immune 
function which may help to establish some of the 
factors that predict response to intervention in this 
group of patients.
 ► It is possible that there is an immunomodulatory ef-
fect of rituximab that will not be detected because 
the trial duration of 2 years is too short.
 ► The likelihood of remission may be different in a 
12-year-old patient with Graves’ hyperthyroidism 
versus a 20-year-old patient, and this consideration 
has not been factored into the trial design. 
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smaller at around 25%, and yet the side effects of CBZ 
are more prevalent in the young, with 20% experiencing 
adverse events that range from relatively minor problems 
such as rashes through to potentially life-threatening 
agranulocytosis.3 4 Establishing a euthyroid state can be 
difficult in the growing person, made more difficult by 
poor medication concordance in some young people.5 6 
Avoiding relapse close to key life events such as exam-
inations can result in prolonged courses of ATD therapy. 
Most young people will ultimately require thyroid gland 
excision (total thyroidectomy) or thyroid gland ablation 
with radioiodine (RI), but these interventions may be 
associated with additional risks in the young person and 
do not represent a cure because the patient is then depen-
dent on lifelong levothyroxine replacement.7 8 Hence, 
there is a pressing need to develop interventions that can 
cure a disease that can have major lifelong implications.8 
Modern immunomodulatory agents have the poten-
tial to ameliorate or ‘switch off’ the immune response to 
produce durable remission in patients with Graves’ hyper-
thyroidism. Rituximab (RTX), a chimeric anti-B cell mono-
clonal antibody (MAb) targeting the surface molecule 
CD20, leads to reductions in B lymphocyte populations 
lasting for around 6 months in more than 95% of people 
following one or two doses.9 CD20 is only expressed on 
pre-B lymphocytes and mature B cells; it is not expressed 
on B lymphocyte stem cells or the committed plasma cell. 
Circulating B lymphocytes are bound by the antibody and 
removed via antibody-dependent cellular cytotoxicity, 
complement-mediated lysis and apoptosis. RTX has been 
successfully used to treat B cell malignancies, with more 
than one million patients treated worldwide in recent 
years.10 It has also been used in a range of autoimmune 
disorders because of its favourable safety profile in adults 
and children.11 12
RTX has recognised disease-modifying activity both 
in people with organ-specific and non-organ specific 
immune-mediated disorders.11–17 B cell depletion with 
RTX has been shown to have disease-modifying effects 
in rheumatoid arthritis, systemic lupus erythematosus 
(SLE), autoimmune thrombocytopaenia, myasthenia 
gravis, and polyangiitis with granulomatosis including 
classical T-cell-mediated autoimmune diseases such as 
multiple sclerosis and type 1 diabetes. B cell depletion at 
sites of active inflammation reduces antigen presentation 
to autoreactive T lymphocytes, leading to amelioration 
of the cytotoxic autoimmune attack. While autoreactive 
B cells may return in some patients following RTX,18 
the impact on disease outcome is not closely linked to 
circulating antibody levels, and the diverse function 
of B cells including their impact on T cell activity may 
explain why there may be an effect of RTX many years 
postadministration.19–22
B lymphocyte depleting immunotherapy appears to 
have disease-modifying activity in adults with Graves’ 
hyperthyroidism; RTX administration has been associated 
with encouraging remission rates, with approximately 
50% of thyrotoxic adults in case reports and case series 
becoming euthyroid following treatment with RTX.23–28 
Many of these patients were selected on the basis of more 
severe disease with relapsed Graves’ hyperthyroidism or 
aggressive orbitopathy. The management of cases where 
there was no clear response to RTX was characterised 
by early intervention with ATD, surgery or RI within the 
first year after RTX therapy, which may have obscured 
a beneficial effect of immunotherapy on thyroid status. 
Graves’ hyperthyroidism and Graves’ orbitopathy (GO) 
have several immunopathogenic features in common, 
including shared autoantigens, and several studies indi-
cate that RTX has the potential to modify the natural 
history of thyroid eye disease.29–31 However, this has not 
been a consistent observation, with one randomised trial 
showing no impact of RTX on GO.32 The difference in 
trial outcome has been reviewed,33 and the differences 
could reflect factors such as the younger age of those 
recruited to the trial in Italy.30
RTX has an excellent safety record in the young and 
has been used extensively in paediatric practice to treat 
autoimmune cytopaenias, juvenile dermatomyositis, juve-
nile idiopathic arthritis, SLE and renal disorders, with 
significant side effects uncommon.16 34 Rates of infec-
tion appear to be low.14 Hypogammaglobulinaemia is a 
possible but very rare side effect in young people and 
may reflect an underlying but previously unrecognised 
immunodeficiency.35 The rare complication, progressive 
multifocal leucoencephalopathy, has been seen almost 
exclusively in adult patients with complex disorders who 
have received multiple immune suppressants (eg, those 
with B cell malignancies, multiorgan refractory SLE).
The aim of this clinical trial is to explore whether RTX 
administration will have a beneficial impact on the disease 
course in young people presenting with Graves’ hyperthy-
roidism. Specifically, we have set out to establish whether 
a single 500 mg dose of RTX, when administered together 
with a 12-month course of ATD, will increase remission 
rates in young people with Graves’ hyperthyroidism.
Previous treatment regimens in adults with Graves’ 
disease or GO have typically used between 1000 and 
2000 mg RTX administered in divided doses. In contrast, 
a single dose of 500 mg RTX was used in a recent trial of 
patients with GO.30 The investigators in this trial subse-
quently reduced the dose of RTX to 100 mg in some of 
their trial patients because complete peripheral B cell 
depletion was still seen with this smaller dose. Our selec-
tion of 500 mg of RTX was a pragmatic decision bearing 
in mind the established efficacy in many disorders of 
2×1000 mg doses versus the observation that a profound 
effect on B cell numbers was still observed with a much 
smaller dose. We were also keen to reduce the complexity 
associated with repeated visits to hospital for an intrave-
nous infusion. By using a modest dose of 500 mg RTX 
on one occasion, we anticipated a meaningful effect on 
immune system function but a reduction in potential 
side effects.27
A course of ATD will be also prescribed in addition 
to a single dose of RTX so that patients are rendered 
 o
n
 22 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024705 on 21 January 2019. Downloaded from 
3Cole M, et al. BMJ Open 2019;9:e024705. doi:10.1136/bmjopen-2018-024705
Open access
clinically and biochemically euthyroid while the immune 
modulating effects of RTX alter the underlying immune 
disease process. A dose-titration ATD regimen will be 
used to reduce the likelihood of a subject having to 
stop ATD medication while still hyperthyroid.36 ATD 
will be stopped before 12 months has elapsed if patients 
become hypothyroid while on the smallest dose of ATD 
(5 mg CBZ alternate days). As well as preventing thyroid 
hormone production, ATD has a specific immunomod-
ulatory effect, including reducing thyroid autoantibody 
concentrations during treatment.37 38 These effects may 
involve alteration of thyroid antigen structure,2 inhibition 
of proinflammatory cytokines or inhibition of T lympho-
cytes by other potential mechanisms.39 An additive or 
indeed synergistic effect of RTX and ATD is theoretically 
possible via combined effects on autoantibody genera-
tion, and the combination of RTX and ATD may increase 
remission rates above those observed in studies to date. 
Another advantage of the immunomodulatory approach 
to autoimmune hyperthyroidism is the potential for inter-
vention to reduce the likelihood of longer term hypothy-
roidism.40 41
MethoDs AnD AnAlysIs
trial objectives
The primary objective is to establish whether a single 
500 mg dose of RTX, when administered together with 
a 12-month course of ATD, is likely to result in a mean-
ingful improvement in the proportion of young people 
with Graves’ hyperthyroidism entering disease remission.
The secondary objectives are to examine (1) the rela-
tionship between thyrotropin receptor antibody (TRAb) 
titre and thyroid hormone status (thyroid stimulating 
hormone [TSH], free thyroxine [FT4] and free tri-io-
dothyronine [FT3]) in recruited subjects at the begin-
ning and end of the trial; (2) whether immune cellular 
response is related to disease outcome by examining the 
relationship between time to recovery of B cell numbers 
measured in peripheral blood to within the local normal 
reference range and thyroid hormone status at the end 
of the trial; (3) whether total dose of ATD is related to 
disease outcome; (4) the time taken for TSH concen-
trations to normalise post-RTX and to describe thyroid 
status, as assessed by TSH, FT4 and FT3 concentrations 
(normal or abnormal), in the period between cessation 
of ATD therapy and the end of the trial in each patient; 
and (5) the safety of the trial treatment regimen by deter-
mining the nature and frequency of adverse events.
trial design
This is an investigator-initiated, open-label, single-arm, 
single-stage, phase II trial using an A’Hern design42 to 
determine whether the proposed new treatment is likely 
to meet a minimum level of efficacy before comparing it 
with standard treatment in a randomised trial. A single-arm 
design has been chosen because use of a control arm 
would require a much larger sample size resulting in a 
longer, more expensive trial when the potential benefit 
of RTX is, as yet, unknown. The design requires specifi-
cation of the smallest remission rate, which if true would 
clearly imply that the treatment warrants further inves-
tigation, and the largest remission rate below which we 
would not wish to proceed to a larger definitive trial.
trial setting
This is a multicentre trial based in seven paediatric 
and seven adult tertiary endocrine units in the cities of 
Birmingham, Edinburgh, Newcastle, Leeds, Sheffield, 
Cardiff and Southampton UK and one secondary paedi-
atric unit in Doncaster, UK.
Inclusion criteria
 ► Excess thyroid hormone concentrations at diagnosis: 
elevated free FT3 and/or FT4 (based on local assay).
 ► Suppressed (unrecordable) TSH (based on local 
assay).
 ► Patients between the ages of 12 and 20 years inclusive 
who are less than 6 weeks from the initiation of ATD 
treatment (CBZ or propylthiouracil [PTU]) for the 
first time.
 ► Elevated thyroid binding inhibitory immunoglob-
ulin or thyroid receptor antibodies (TRAb including 
thyroid binding inhibiting immunoglobulin [TBII]) 
based on local assay. Patients may or may not have a 
raised thyroid peroxidase antibody titre.
 ► All patients must be willing to use effective forms 
of contraception for 12 months post-treatment with 
RTX.
 ► If women are of childbearing potential, they must 
have a negative pregnancy test at screening. This will 
need to be repeated on the day of RTX administration 
if more than 7 days has elapsed since the screening 
visit or a negative pregnancy test.
 ► Able and willing to adhere to a 2-year trial period.
exclusion criteria
 ► Previous episodes of autoimmune thyroid disease.
 ► Patients with an active, severe infection (eg, tubercu-
losis, sepsis and opportunistic infections) or severely 
immunocompromised patients.
 ► Patients with known allergy or contraindication to 
CBZ and PTU.
 ► Participants with previous use of immunosuppressive 
or cytotoxic drugs (including RTX and methylpredni-
solone, but excluding inhaled glucocorticoid and oral 
glucocorticoid for asthma or topical glucocorticoid 
for eczema).
 ► Chromosomal disorders known to be associated with 
an increased risk of autoimmune thyroid disease, 
including Down’s syndrome and Turner syndrome.
 ► Pregnancy, planned pregnancy during the trial period 
or current breast feeding.
 ► Absence of informed consent from parent/legal 
guardian for participants age <16 years.
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 ► Participants with significant chronic cardiac, respira-
tory or renal disorder or non-autoimmune liver 
disease.
 ► Participants with known allergy or contraindication to 
RTX or methylprednisolone.
 ► Participants with evidence of hepatitis B/C infection, 
assessed by determining hepatitis ‘B’ surface antigen 
(HBsAg) status, hepatitis ‘B’ Core antibody (HB Core 
antibody) status and hepatitis ‘C’ virus antibody (HCV 
antibody) status.
 ► Participants in families who know they will be moving 
out of the catchment areas during the 2 years following 
RTX treatment.
 ► Participants currently involved in any other clinical 
trial of an investigational medicinal product (IMP) or 
who have taken an IMP within 30 days prior to trial 
entry.
Patient identification
Potentially eligible patients will be referred by their local 
clinician (general practitioner, paediatrician, physician 
or endocrinologist) or through self-referral via national 
organisations such as the British Thyroid Foundation 
(BTF) to a clinician with delegated responsibility to 
discuss the trial.
screening, recruitment and consent
Informed consent discussions will be undertaken by 
appropriate site staff, with an opportunity for the patient 
and the parent/guardian to ask questions. Following 
receipt of the patient information sheet (PIS), partic-
ipants will be given a minimum of 24 hours to decide 
whether or not they would like to participate. As part of 
the consent discussions, the requirement to use effec-
tive contraception must be discussed. The PIS states that 
after the patient has given consent, they will be required 
to provide a blood sample and undergo a pregnancy 
test (if female) to confirm that they are not pregnant 
and that there is no evidence of hepatitis B/C infection. 
Some sites will also need to carry out HIV screening and 
QuantiFERON tests to confirm that the patients do not 
have tuberculosis and HIV (as per their local clinical 
policies) before a patient can be confirmed as eligible. 
Those wishing to take part will provide written informed 
consent/assent prior to trial-specific procedures/inves-
tigations. The information sheets and consent/assent 
forms are shown in online supplementary appendix 1 a, 
b,  c and d.
If thyroid antibody status (TRAb or TBII) was not 
determined at diagnosis, then this will be assessed at this 
consent and screening visit. The patient will be classi-
fied as a screen fail if they are found not to be eligible 
at this point. Ineligible patients will be notified via tele-
phone and not asked to come in for a further trial visit. A 
screening log will be kept securely at each of the recruiting 
units (paediatric and adult units) to document details of 
eligible patients who have screen failed or declined to 
participate in the trial, including any reasons available. 
The right to refuse to participate without giving reasons 
will be respected.
Intervention
RTX will be administered as a 500 mg dose by slow intra-
venous infusion under cover with methylprednisolone 
125 mg intravenously, chlorpheniramine 10 mg intrave-
nously, and 500 mg (12–16 years of age) or 1 g (>16 years) 
of paracetamol (orally). The RTX infusion will be started 
at a rate of 50 mg/hour, increasing by 50 mg/hour every 
half hour if tolerated; otherwise the infusion will either 
be maintained at the current rate or stopped and then 
restarted after 30 min. If the RTX infusion is tolerated 
and the rate increased as above, then the infusion will 
take 3.25 hours. Symptoms which are considered intoler-
able are angioedema, low blood pressure and difficulty 
breathing; if any are observed, the treatment will be 
stopped immediately, only to be restarted once symptoms 
have resolved. Vital signs including blood pressure will be 
measured every 30 min during the RTX infusion and for 
2 hours afterwards.
RTX administered may only take place following confir-
mation that the patient is hepatitis B/C antibody-nega-
tive and within 7 days of a negative test for pregnancy 
(women). Administration of live vaccines is contraindi-
cated or not recommended for at least 6 months following 
RTX administration.
AtD therapy (CbZ and Ptu)
A 12-month course of ATD will be administered to induce 
a euthyroid state in the months following diagnosis. 
Therapy will normally be with CBZ, which can be adminis-
tered once daily. PTU is a second-line therapy because of 
the increased likelihood of hepatic failure with this drug. 
It is proposed that CBZ dose be titrated against prevailing 
thyroid function tests in order to maintain a euthyroid 
state. Clinicians will be encouraged to follow the schedule 
outlined in table 1 when administering ATD to patients 
enrolled into this clinical trial, although the managing 
clinician can elect not to follow the above framework if 
their assessment of the overall clinical picture suggests 
that this is in the patients’ best interests. PTU can be 
administered on the basis that 5 mg of CBZ is equivalent 
to 50 mg PTU. If patients become hypothyroid (with an 
elevated TSH and low FT4/FT3 level) on the smallest 
daily dose of CBZ (5 mg) or PTU (50 mg), then the ATD 
can be administered on alternate days. If patients are still 
hypothyroid, then the ATD will be stopped before 12 
months has elapsed following RTX therapy.
Any participants who develop unacceptable toxicity to 
CBZ (notably neutropaenia with a neutrophil count less 
than 0.5×109/L) will stop ATD immediately. Participants 
with a neutrophil count between 0.5 and 1.0 can remain 
on ATD if well. The neutrophil count should be repeated 
after approximately 1–2 weeks or as clinically indicated to 
confirm that it has not fallen to less than 0.5×109/L. PTU 
can be commenced as a replacement ATD in the case of 
adverse events that do not involve hepatic dysfunction or 
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neutropaenia. The increased risk of liver dysfunction on 
PTU will be discussed with participants and their fami-
lies prior to commencing PTU. Patients on PTU will have 
liver function checked at each visit and PTU stopped if 
ALT or bilirubin is elevated (2× above the upper limit 
of normal). If patients are unable to tolerate ATD, then 
it may be feasible to monitor patients off treatment or 
manage them symptomatically with beta blockade on 
the basis that RTX may alter the disease natural history 
and result in remission without further ATD. This option 
can be discussed with the participant/the participant 
and their family. Other potential means of maintaining 
a euthyroid state can be discussed with the trial manage-
ment team.
Patients who relapse in the second year of the trial will 
be encouraged to return to ATD in the first instance.
outcome measures
Primary
The number of subjects in remission at 2 years following 
a single dose of RTX and a 12-month course of ATD is the 
primary trial endpoint: this is equivalent to the number 
who have not relapsed. Subjects will be deemed to have 
relapsed if they are receiving any concomitant ATD medi-
cation in the second year post-RTX administration, or 
have undergone surgical (thyroidectomy) or RI treat-
ment because of hyperthyroidism at any time following 
RTX administration. They will also be deemed to have 
relapsed if serum TSH is less than the lower limit of the 
normal laboratory reference range and serum FT3 is 
above the upper limit of the normal laboratory reference 
range at 2 years.
Secondary
1. TRAb titre and related thyroid hormone status at the 
time of RTX administration and 2 years post-RTX.
2. Time to recovery of B cell lymphocyte numbers in pe-
ripheral blood to the normal local lab reference range 
in relation to thyroid hormone status.
3. Cumulative dose of ATD (mg/kg) in relation to thy-
roid hormone status 2 years post-RTX.
4. Time taken for TSH and thyroid hormone concentra-
tions to normalise to within the local laboratory refer-
ence range post-RTX, and describe biochemical thy-
roid status in the period between cessation of ATD and 
2 years post-RTX in each patient.
5. The frequency and nature of adverse events.
Visit details and assessments
Following screening and consent, RTX is administered at 
the baseline visit (week 0). Subsequent visits are sched-
uled until 24 months; the details are provided in table 2. 
In addition, after each visit in the first 12 months, partic-
ipants are contacted by telephone to document changes 
in ATD dosages. Calls should be completed within 10 days 
of the visit.
HBsAg, HB Core antibody and HCV antibody status is 
checked at screening/consent to establish hepatitis status 
to determine if the patient can be entered into the trial. 
A full blood count is conducted to look for evidence of 
Table 1 CBZ dose adjustment according to changing thyroid hormone status
Week/stage of trial Thyroid hormone level: FT4 and FT3 (pmol/L) CBZ dose (mg)
Presentation 20 mg CBZ once daily (consider 10 mg in the case 
of mild hyperthyroidism, FT3<10).
Week 4 Biochemically hypothyroid (low FT4, FT3 not 
raised).
Reduce to 5 mg.
FT3 normal and FT4 falling. Consider reducing from 20 mg to 10 mg, or from 10 
to 5 mg.
FT3 elevated. Continue prior dose.
Week 8 Biochemically hypothyroid (low FT4, FT3 not 
raised).
Reduce to 20 mg, 10 mg, 5 mg, or reduce CBZ to 
5 mg alternate days.
FT3 normal and FT4 falling. Reduce from 20 mg to 10 mg, from 10 mg to 5 mg, 
or remain on 5 mg.
FT3 elevated but improving. Continue prior dose.
FT3 raised or increasing further. Consider increasing CBZ by 10 mg daily.
Week 12 and beyond Biochemically hypothyroid (low FT4, FT3 not 
raised).
Reduce to 10 mg, 5 mg or reduce CBZ to 5 mg 
alternate days.
FT3 normal (or elevated with low FT4). Continue current dose.
FT3 elevated. Consider increasing CBZ by 10 mg daily or 5 mg 
daily if previously euthyroid.
Week 16 and beyond TSH elevation (>4 mU/L) (TSH takes precedence 
over thyroid hormone levels).
Reduce CBZ dose by 5–10 mg daily.
TSH still suppressed. Follow guide above for week 12.
CBZ, carbimazole; FT3, free tri-iodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone. 
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change in white cell number (a recognised side effect 
of ATD). Lymphocyte subsets including T cells (CD3+), 
helper T cells (CD4+), cytotoxic T cells (CD8+), B cells 
(CD19+) and class switch B cells (CD27+ IgD−) and 
serum immunoglobulin (Ig) levels (IgG, IgM, IgA) are 
measured to look at the impact of RTX (anti-B cell MAb) 
on B and T cell populations and immunoglobulin levels 
(produced by plasma cells that differentiate from B cells).
Specific vaccine antibodies (against tetanus, haemoph-
ilus influenzae type B and pneumococcus) are assessed at 
baseline and at 12 and 24 months to look for evidence of 
falling levels as a consequence of the intervention.
At each visit, concomitant medications are recorded, an 
adverse event check is performed and thyroid function 
(TSH, FT4 and FT3) is assessed.
We plan to undertake exploratory analyses of immune 
system function on blood samples obtained prior to the 
RTX infusion at baseline and then after 12 months and 
24 months. This will include measurement of a range of 
novel factors involved in immune system activity, including 
B lymphocyte activating factor, a proliferating-inducing 
ligand and B lymphocyte chemoattractant (CXCL13). 
These data will be analysed separately from the main trial.
Withdrawal
Participants have the right to withdraw from the trial at 
any time, including during the single infusion of RTX, 
without having to give a reason. The patient will still be 
asked to complete follow-up. Sites will need to record 
the amount of RTX that was administered prior to the 
patients’ withdrawal. Investigator sites should try to ascer-
tain the reason for withdrawal and document this reason 
within the case report form and the participant’s medical 
notes.
As this is a single-dose administration, it is not antici-
pated that the investigator would withdraw a patient from 
Table 2 Schedule of events
Assessments/
Intervention
Trial period
Screening/Consent Trial intervention Follow-up
Week −6 to 0 0 4 8 12 16 20 28 36 44 52 65 78 91 104
Confirmation of eligibility X X
Informed consent and 
assent
X
HBsAg, HB Core and HCV 
antibodies
X
Pregnancy test (women) X X X
Medical history X
Clinical examination X X X X X X X X X X X X X X
Height X X X X X
Weight X X X X X X X X X X X X X X
RTX infusion X
ATD regimen X X X X X X X X X X
ATD compliance X X X X X X X X X
Concomitant medication X X X X X X X X X X X X X X
Adverse and serious 
adverse event
X X X X X X X X X X X X X X
Thyroid function (TSH, FT4 
and FT3)
X X X X X X X X X X X X X X
Liver function (ALT and 
bilirubin) if on PTU
X X X X X X X X X X X X X X
Thyroid antibodies (TRAB 
and TPO)
X X X X X X
Lymphocyte subsets* X X X X X X X
Full blood count X X X X X X X
Immunoglobulin levels 
(IgG, IgM, IgA)
X X X X X X
Specific antibody 
levels (tetanus, Hib, 
pneumococcus)
X X X
Thyroid function (TSH, FT4 
and FT3)—central analysis
X X X
Serum for exploratory 
analyses
X X X
ATD dose is adjusted at each visit if required.
*Lymphocyte subsets: T cells (CD3), helper T cells (CD4), cytotoxic T cells (CD8), B cells (CD19) and class switch B cells (CD27+ IgD−).
ALT, alanine transaminase; ATD, antithyroid drug; FT3, free tri-iodothyronine; FT4, free thyroxine; HB Core, hepatitis ‘B’ Core antibody; HBsAg, hepatitis ‘B’ surface antigen; 
HCV, hepatitis ‘C’ virus antibody; Hib, haemophilus influenzae type B; PTU, propylthiouracil; RTX, rituximab; TPO, thyroid peroxidase; TRAb, thyrotropin receptor antibody; 
TSH, thyroid stimulating hormone. 
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treatment (the infusion would be slowed down accord-
ingly—see the Intervention section). If the RTX infusion 
has to be stopped completely and cannot be recom-
menced, then those subjects receiving less than 100 mg 
RTX will be reviewed according to the protocol for safety 
reasons only. Should a participant withdraw from the 
trial, then every effort will be made to obtain follow-up 
data, with the permission of the patient.
Participants who withdraw from the trial will not be 
replaced.
sample size
Formal justification to proceed to a larger randomised 
trial is based on observing a minimum number achieving 
remission 2 years post-RTX administration; this number is 
referred to as the critical number.42 The critical number 
depends on the desired and unacceptable remission 
rates, set at 40% and 20%, respectively, and the error 
levels set at 10% alpha (type I) and 20% beta (type II). 
The remission rate corresponding to the critical number 
will lie between 40% and 20% and will be specified and 
stored separately in the Statistics trial master file (TMF). 
If the true remission rate is 40%, there is an 80% chance 
(power) of proceeding to a further trial; if the true remis-
sion rate is 20%, there is a small 10% (alpha) chance of 
proceeding to a further trial. With these parameters the 
target recruitment is 27 patients who will receive RTX. 
This is the smallest number of patients which satisfies the 
design criteria, assuming a 10% loss to follow-up.
statistical analysis
Patients will receive a single dose of RTX once they have 
fulfilled the inclusion and exclusion criteria. In the event 
that RTX is not well tolerated, only patients who were 
able to receive more than 100 mg of RTX will be included 
in the statistical analysis.
Analysis of the primary outcome measure
The number of patients in remission 2 years after RTX 
administration will be compared with the critical number. 
This is equivalent to a formal comparison of the hypoth-
eses that the remission rate is greater than or equal to 
40% as opposed to less than or equal to 20%. The primary 
outcome measure, remission rate, will be presented with a 
one-sided 90% lower bound. If this phase II trial provides 
evidence that the true remission rate is plausibly 40% or 
more, 2 years after a single dose of RTX and a 12-month 
course of ATD, then this will indicate a likely effect of 
RTX on disease outcome and justify a randomised effi-
cacy evaluation of this adjuvant RTX regimen.
Analysis of secondary outcome measures
1. The distribution of TRAb titres will be compared be-
tween patients in and out of remission by graphical 
summary, numerical summary statistics (median and 
IQR) and a Mann-Whitney test.
2. Time to recovery of peripheral blood B cell lymphocyte 
numbers (CD19+ cells) to above 70% of the patient’s 
pre-RTX level in relation to thyroid hormone status. 
This will be compared between patients in and out of 
remission by graphical summary, numerical summary 
statistics (median and IQR) and a Mann-Whitney test.
3. Cumulative dose of ATD (CBZ) in mg/kg in relation 
to thyroid hormone status. This will be compared be-
tween patients in and out of remission by graphical 
summary, numerical summary statistics (median and 
IQR) and a Mann-Whitney test.
4. We will assess the time taken for TSH concentrations 
to normalise (increase above 0.1mU/L) post-RTX 
and describe biochemical thyroid status, as assessed 
by TSH, FT4 and FT3 concentration, in the period be-
tween cessation of ATD therapy at the end of year 1 
and the end of the trial. Specifically we will plot the 
time taken for TSH to normalise in individual patients 
and determine the proportion of time that TSH, FT4 
and FT3 concentrations are within the normal refer-
ence range in the period between ATD stopping (end 
of year 1) and trial end (end of year 2).
5. The frequency and nature of adverse events.
Criteria for the premature termination of the trial
The criteria for stopping the trial will be if a patient 
dies from an RTX treatment-related infection, or if two 
patients experience the same serious unsuspected serious 
adverse reaction (SUSAR) which has severe or life-threat-
ening consequences.
safety reporting
We do not aim to collect adverse events such as minor 
trauma (scratches, cuts) in patients who are otherwise 
well. Adverse events will otherwise be classified according 
to whether they are:
1. Infections (minor: self-limiting infection such as the 
common cold; modest: non-self-limiting where an anti-
biotic is prescribed but the clinical course and recovery 
is not related to the underlying condition and its treat-
ment; or severe: where antibiotic therapy ± other thera-
py is required with the infection related to drug effects 
on immune function).
2. Immune function-related such as neutropaenia.
3. Related to the skin, for example, rashes.
4. Related to the musculoskeletal system, such as joint 
pain.
5. Related to gastrointestinal upset.
6. Related to hepatic function.
7. Others.
The trial will be stopped if a patient dies from an RTX 
treatment-related infection or if two patients experience 
the same SUSAR which has severe or life-threatening 
consequences.
According to section 4.6 of the summary of product 
characteristics (SmPC) (Mabthera [the product name for 
RTX]  100 mg and 500 mg concentrate for solution for 
infusion), RTX should not be administered to pregnant 
women. The SmPC states that ‘Rituximab should not be 
administered to pregnant women unless the possible 
benefit outweighs the potential risk’. Due to the long 
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retention time of RTX in B cell-depleted patients, women 
of childbearing potential need to use effective contra-
ceptive methods during treatment and for 12 months 
following RTX therapy (in line with the SmPC for RTX). 
If a female participant becomes pregnant within 12 
months of taking the RTX drug, the details of the preg-
nancy need to be reported to the chief investigator, trial 
manager and sponsor within 24 hours of the site learning 
of its occurrence on the pregnancy reporting form.
If a patient or their partner (where the participant is 
male) becomes pregnant, within 12 months of taking 
RTX, the pregnancy must be reported as per the trial-spe-
cific guidance document for pregnancy reporting and 
followed up to completion of pregnancy.
Patient and public involvement
We were keen to involve patients including those with 
Graves’ hyperthyroidism and their families in the 
design of this clinical trial. We therefore discussed the 
proposed trial with patients who had Graves’ hyperthy-
roidism within our clinical service and liaised with the 
Young Person’s Advisory Group (YPAG) in the North of 
England. We also discussed the trial with the BTF, and it 
was clear from these discussions that improving the treat-
ment options for young people with this condition was an 
important area. YPAG and a representative from the BTF 
helped to refine the trial protocol and the patient infor-
mation sheets. A member of the BTF was part of the trial 
steering committee, and the BTF published information 
regarding the trial on their website and facilitated recruit-
ment by providing information to potential participants.
We intend to notify participants in writing regarding 
the trial outcome.
ethICs AnD DIsseMInAtIon
Trial oversight consists of Trial Steering Committee 
(TSC), Data Monitoring Committee (DMC) and Trial 
Management Group (TMG). The TSC comprises 
an independent chair and three other independent 
members including a statistician. The DMC consists 
of three independent members, an endocrinologist 
(chair), immunologist and a statistician. The TMG will 
be responsible for overseeing the progress of the trial. 
The day-to-day management of the trial will be coor-
dinated by the Newcastle Clinical Trials Unit, which 
will also be responsible for informing sites regarding 
protocol modifications and updates. Data management 
will be undertaken in accordance with the Newcastle 
University Clinical Trials Unit Standard Operating 
Procedures.
The results of this trial will be distributed widely at 
international endocrine meetings, including the Euro-
pean Society for Paediatric Endocrinology annual 
meeting. The results will be published in the peer-re-
viewed literature and distributed via patient support 
groups including the BTF.
DIsCussIon
Graves’ disease remains a challenge for young people 
and their families, with significant disadvantages asso-
ciated with all standard treatment modalities. Most 
young people will ultimately be treated with thyroid 
hormone replacement which is not ideal from a prac-
tical, financial and quality of life perspective.43 The 
management of Graves’ hyperthyroidism is currently 
under review by National Institute for Health and Care 
Excellence.
This is a proof-of-concept trial that may be the 
precursor to a phase III trial. The limitations of the 
trial design include the need to adopt a largely prag-
matic approach to the selection of the RTX dose and 
the fact that an impact on disease course may not be 
detected by a 2-year trial. On the other hand, patients 
who remit by 2 years may still be at risk of relapse at a 
later stage. There is also a risk that patients will experi-
ence side effects from ATD therapy which means this 
has to be stopped. If so, then definitive treatment may 
be required before the impact of RTX on the disease 
course can be elucidated. There is also a need to be 
cautious about assuming that remission rates following 
a course of ATD in a 12-year-old patient with Graves’ 
hyperthyroidism are similar to those in someone who 
is 20 years of age. Remission rate may therefore reflect 
the age of trial participants as well as the impact of the 
treatment regimen.
We feel that there are three disadvantages from the 
patient’s perspective when taking part in this trial. 
First, the infusion involves a day spent in hospital. The 
second disadvantage is the potential risk of adverse 
events, notably infections, although the literature 
does not suggest significant issues in an otherwise 
healthy and immune competent group of subjects like 
young patients with Graves’ hyperthyroidism who have 
received one or two doses of RTX. Finally there is the 
uncertainty about whether the intervention will impact 
on disease outcome favourably.
The number of clinic visits will be similar to patients 
with Graves’ managed routinely and will help to ensure 
that patients’ biochemistry is monitored carefully.
ATD does not cure young patients with Graves’ in 
the short term and is only associated with resolution 
of the hyperthyroid state in a minority of patients after 
several years of treatment. Surgery and RI remove or 
destroy the gland and hence are not a cure either. 
RTX provides the prospect of an earlier remission in 
patients with Graves’ hyperthyroidism who are there-
fore less likely to experience the side effects of ATD. 
RTX may cure patients who would otherwise not have 
been cured by ATD, and it may reduce the likelihood 
of long-term hypothyroidism. Repurposing RTX for 
this indication would mean an immediately translat-
able therapy with a well-established and favourable 
side effect profile, and a likely reduction in costs now 
that it is off-patent.
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trIAl stAtus
This manuscript is based on trial protocol V.4.0 dated 
27 November 2017. The adjuvant rituximab, a potential 
treatment for the young patient with graves’ hyperthy-
roidism (RiGD) trial, opened to recruitment in October 
2016 and is due to close to recruitment in October 2018.
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